Dec 6 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and ...

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Vertex: ...

Vertex Pharmaceuticals has seen its fair value estimate inch up from about $480 to roughly $485 per share as analysts refresh their models around a more constructive long term growth narrative.

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

Vertex stock reached a 52-week low, touching 19.17 USD, marking a significant downturn for the company. Over the past year, Vertex has experienced a steep decline, with its stock value plummeting by ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

New fear unlocked: spontaneous black hole implosion. Fresh research predicts that planets may be able to accumulate enough dark matter to suddenly form a black hole at their core. As the intruder ...

CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ CEO Sam Altman called a strange graph in its GPT-5 presentation a ‘mega chart screwup.’ is a senior reporter ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...